Vagistat-1 "broader spectrum" may be advantage over other treatments, BMS says.
This article was originally published in The Tan Sheet
Executive Summary
BRISTOL-MYERS SQUIBB VAGISTAT-1 BROADER SPECTRUM is being highlighted by the company as one potential benefit of the new one-dose OTC vaginal yeast infection product. Speaking at a March 5 teleconference on the approval of the 6.5% tioconazole ointment, BMS Executive Medical Director Carole Sampson Landers, MD, said that in vitro, the product's active ingredient has "a little bit broader [spectrum] than some of the other azoles" on the market.